Novartis announced an additional round of layoffs at its U.S. headquarters, adding about 60 more roles linked to the East Hanover site later this year. The company said the move follows earlier U.S. headquarters reductions tied to its multiyear workforce plan. The latest reductions are tied to ongoing efforts to evolve field sales teams in oncology, rheumatology, dermatology and neuroscience, and are separate from prior rare-disease and cardiovascular commercial restructurings. WARN filings indicate the new round begins in late July and runs through late November. For biotech and vendors, the updates reinforce that big pharma is reallocating spend and headcount ahead of major patent cliffs, including those associated with core franchises due in 2026.